Top

Category: Cell and Gene Therapy


Cell and Gene Therapy, Industry

New findings speed progress towards affordable gene therapy

November 20, 2020

Via: ScienceDaily

Researchers used metal-organic frameworks (MOFs) enhanced with a green tea phytochemical coating to target human prostate cancer cells for the first time. The new method for deploying the genetic snipping tool directly into target cells is a big step towards […]


Cell and Gene Therapy, Industry, News

Catalent Appoints Open Innovation, Biologics, Cell and Gene Therapy VP

November 19, 2020

Via: Contract Pharma

Catalent has appointed Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. In this new role, Dr. Mahdavi will join a team of experts in Catalent’s Science and Technology Group that works with customers […]


Cell and Gene Therapy, Industry

Boosting Capabilities in Gene and Cell Therapy Bioprocessing

November 17, 2020

Via: Genetic Engineering and Biotechnology News

A new company has been founded to supply software for managing cell & gene therapy manufacturing. Autolomous, founded in February 2019, has already secured four different clients whom they hope to assist with digitizing and streamlining their workflows. “There’s a […]


Cell and Gene Therapy, Industry

New Therapeutic Target Identified for Breast Cancer Treatment

November 16, 2020

Via: Genetic Engineering and Biotechnology News

Lemur tyrosine kinase 3 (LMTK3) is associated with cell proliferation and endocrine resistance in breast cancer. Now, a team of researchers from the University of Sussex has completed a five-year study that provides evidence for a potential new target for […]


Cell and Gene Therapy, Industry

New Targeted Approach Could Prevent Toxicities Associated with Neurological Gene Therapies

November 12, 2020

Via: BioSpace

Researchers from Penn Medicine have developed a new targeted approach that modifies viral vectors and inhibits toxicities in the sensory neurons of dorsal root ganglia (DRG) that commonly occur following the use of gene therapy for neurological diseases. This strategy […]


Cell and Gene Therapy, Industry

Does Talaris’ Investigational Cell Therapy Have Potential to Be a ‘Pipeline in a Product’?

November 10, 2020

Via: BioSpace

Talaris Chief Executive Officer Scott Requadt sees FCR001, the company’s investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications). In fact, it was that versatility of […]


Cell and Gene Therapy, Industry

Scientists use gene therapy to regenerate damaged optic nerve fibers

November 5, 2020

Via: Medical News

Scientists have used gene therapy to regenerate damaged nerve fibers in the eye, in a discovery that could aid the development of new treatments for glaucoma, one of the leading causes of blindness worldwide. Axons – nerve fibers – in […]


Cell and Gene Therapy, Industry

Treating multiple sclerosis with an antigen-specific cell therapy

November 4, 2020

Via: FierceBiotech

Existing multiple sclerosis therapies systematically modulate the immune system to dampen its erroneous attack on the protective myelin sheaths around nerve cells, which is the hallmark of the autoimmune disease. But this approach puts patients at a higher risk of […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Scientists Map Sensitivity of Thousands of Genes to Chemical Exposure

November 2, 2020

Via: Genetic Engineering and Biotechnology News

Scientists at the University of Massachusetts, Amherst, have used what they claim is an unprecedented objective approach to identify which genes and molecular pathways— including mechanisms involving aging, lipid metabolism, and autoimmune disease—are most sensitive to chemical exposure. Headed by […]


Cell and Gene Therapy, Industry

Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility

October 29, 2020

Via: Contract Pharma

Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium. Catalent will purchase the shares of SCTS, currently held by […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Bayer to Pay up to $4B for Gene Therapy Firm AskBio

October 28, 2020

Via: Contract Pharma

Bayer AG has acquired Asklepios BioPharmaceutical, Inc. (AskBio) for $2 billion upfront and potential success-based milestone payments of up to $2 billion. The U.S.-headquartered biopharma specializes in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s […]


Cell and Gene Therapy, Industry

Lysogene Confirms Child’s Death in Phase II/III Gene Therapy Trial

October 26, 2020

Via: Genetic Engineering and Biotechnology News

A five-year-old girl with Mucopolysaccharidosis Type IIIA (MPS IIIA) has died in the Phase II/III AAVance clinical trial (NCT03612869), designed to evaluate the efficacy of Lysogene’s gene therapy candidate LYS-SAF302 in improving or stabilizing the neurodevelopmental state of MPS IIIA […]